Literature DB >> 17300446

Clinical and epidemiological features of canine leptospirosis in North Queensland.

R I Miller1, S P Ross, N D Sullivan, N R Perkins.   

Abstract

OBJECTIVE: To evaluate the clinical signs, results of clinical pathology and serology tests, and treatment outcome of clinical leptospirosis in 40 dogs from North Queensland.
DESIGN: Retrospective study from January 1995 to August 1999. PROCEDURE: Case records were reviewed for age, breed, sex, month of submission, geographical location and presenting clinical signs in 40 dogs with titres of > or = 200 for leptospirosis by the microscopic agglutination test. A biochemistry panel and complete blood count were performed on 18 dogs.
RESULTS: Canine leptospirosis occurred most frequently during the summer and autumn particularly in the 'wet' tropical coastal areas of Mackay and Cairns. Fewer cases were seen in the Atherton Tablelands and 'dry' tropics around Townsville. Young and male dogs were more commonly affected. Most cases were caused by L australis (80%) and L zanoni (15%) with individual cases of L hardjo and L copenhageni. All dogs showed a distinctive multiorgan disease pattern including renal failure and cholestatic hepatopathy. Presenting clinical signs were related to these disease syndromes and included jaundice, vomiting, lethargy, inappetence, dehydration, pyrexia, abdominal pain and diarrhoea. Just over 50% of the dogs in the present study failed to recover. Clinical biochemical changes indicative of renal failure and cholestasis were significantly less severe in dogs that recovered compared with dogs that did not survive.
CONCLUSIONS: Clinical pathology testing should be performed on all dogs presented for illness in the endemic areas so as to help make a presumptive diagnosis and assist in determining the prognosis as soon as possible. The presumptive diagnosis should be confirmed serologically.

Entities:  

Mesh:

Year:  2007        PMID: 17300446     DOI: 10.1111/j.1751-0813.2006.00089.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  8 in total

1.  Increase in seroprevalence of canine leptospirosis and its risk factors, Ontario 1998-2006.

Authors:  Gillian D Alton; Olaf Berke; Richard Reid-Smith; Davor Ojkic; John F Prescott
Journal:  Can J Vet Res       Date:  2009-07       Impact factor: 1.310

2.  2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention.

Authors:  J E Sykes; K Hartmann; K F Lunn; G E Moore; R A Stoddard; R E Goldstein
Journal:  J Vet Intern Med       Date:  2010-12-13       Impact factor: 3.333

Review 3.  Leptospiral pathogenomics.

Authors:  Jason S Lehmann; Michael A Matthias; Joseph M Vinetz; Derrick E Fouts
Journal:  Pathogens       Date:  2014-04-10

4.  Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.

Authors:  A Barthélemy; M Magnin; C Pouzot-Nevoret; J-M Bonnet-Garin; M Hugonnard; I Goy-Thollot
Journal:  J Vet Intern Med       Date:  2016-12-02       Impact factor: 3.333

Review 5.  Emesis in dogs: a review.

Authors:  C Elwood; P Devauchelle; J Elliott; V Freiche; A J German; M Gualtieri; E Hall; E den Hertog; R Neiger; D Peeters; X Roura; K Savary-Bataille
Journal:  J Small Anim Pract       Date:  2010-01       Impact factor: 1.522

6.  Emerging leptospirosis in urban Sydney dogs: a case series (2017-2020).

Authors:  C Griebsch; N Kirkwood; M P Ward; W So; L Weerakoon; S Donahoe; J M Norris
Journal:  Aust Vet J       Date:  2022-01-25       Impact factor: 1.343

Review 7.  Recent advances in canine leptospirosis: focus on vaccine development.

Authors:  Henricus Lbm Eric Klaasen; Ben Adler
Journal:  Vet Med (Auckl)       Date:  2015-06-19

8.  Leptospirosis is an emerging infectious disease of pig-hunting dogs and humans in North Queensland.

Authors:  Bronwyn Orr; Mark E Westman; Richard Malik; Auriol Purdie; Scott B Craig; Jacqueline M Norris
Journal:  PLoS Negl Trop Dis       Date:  2022-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.